** Shares of Tango Therapeutics TNGX.O up 1% at $31.87 in premarket trading Weds after upsized $600 mln follow-on priced

** Biotech firm late Tues sold ~18.2 mln shares and pre-funded warrants to buy ~1.8 mln shares at $30, a 4.9% discount to last sale

** On Mon, TNGX stock soared 53% after co's experimental pancreatic cancer drug vopimetostat, in combination with Revolution Medicines' RVMD.O daraxonrasib, showed strong early results in a small study

** Subsequently, TNGX late Mon launched $500 mln stock offering

** Co intends to use net offering proceeds for general purposes, including R&D, expenses for pivotal trial and preparation for potential commercialization of one or more of its product candidates, among other purposes, per the prospectus

** JP Morgan, Leerink, Cantor Fitzgerald and Stifel joint bookrunners

** Boston, Massachusetts-based TNGX has ~144.6 mln shares outstanding

** TNGX stock finished up 2% on Tues before hitting intraday record high of $32.79. At close, stock up 256% YTD

** Avg rating of 12 analysts is "buy"; median PT $36, according to LSEG data